The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 116 participants.

Also called NCT07314047

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 116 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07314047
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07314047. Randomized; no masking; primary purpose treatment. Start 2024-05-28 (actual); primary completion 2025-05-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation
Acronym
PARTNER
Condition
Brain Arteriovenous Malformation
Condition
Arteriovenous Fistula
Intervention (Device)
liquid embolic agent
Lead sponsor
MicroPort NeuroTech Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07314047
Content hash
7696ffa28d8afa3996e8379a5b19440c1707c81f01e69084a5f1caa68b03d73a